Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 25, 2025
Product Development
Amylin is back with Novo’s positive amycretin data
Injectable amycretin shows 24% placebo-adjusted weight loss, giving it the lead in efficacy — at least for now
BioCentury | Dec 17, 2024
Product Development
Obesity newcos aim for differentiation
New targets start to outnumber incretins among start-ups exploring paths to deeper, higher-quality weight loss
BioCentury | Oct 25, 2024
Finance
Septerna’s GPCRs draw strong demand in $288M IPO
BioCentury’s Financial Report: ProQR’s $75M raise, Seaport’s $225M series B and more
BioCentury | Oct 7, 2024
Deals
AstraZeneca, Hong Kong-based CSPC in deal for dyslipidemia therapy
Deals report: Recordati acquires Enjaymo from Sanofi, and updates from BioMarin-Camp4, Editas-DRI and more
BioCentury | Oct 1, 2024
Data Byte
Five PDUFA dates on FDA’s October agenda
Decisions include Opdivo as perioperative therapy for NSCLC, and a Lumakras combination for mCRC
BioCentury | Aug 9, 2024
Market Access
Lilly shares resume upward climb on growing tirzepatide sales
Novo sales wobble as Danish pharma looks ahead to 2H24 obesity readouts
BioCentury | Jun 26, 2024
Product Development
Clinical Report: Metabolic readouts from Innovent, Zealand, Poltreg
Plus: New data from Wave, G1 and Jazz
BioCentury | Jan 20, 2024
Finance
Buysiders are all about market-creating catalysts in 2024
BioCentury’s 32nd Buyside View finds MASH, obesity and pain are among the year’s most closely-watched categories
BioCentury | Jan 9, 2024
Deals
Jan. 9 Quick Takes: Precision deal gets TG entry into autoimmune CAR T race
Plus: Pfizer’s, Genmab’s Tivdak gets priority review for full approval and more from Astellas, Cumulus, Pfizer and Innovent
Items per page:
1 - 10 of 105